TABLE 1.
Summary of baseline characteristics in pediatric and adult patients with GPA/MPA who received rituximab in PePRS or RAVE
| Pediatric patients in PePRS 22 (N = 25) | Adults in RAVE 20 (N = 97 a ) | Total (N = 122) | |
|---|---|---|---|
| Age, median (range), years | 14 (6–17) | 55 (16–92) | 50 (6–92) |
| Sex, n (%) | |||
| Male | 5 (20) | 45 (46) | 50 (41) |
| Female | 20 (80) | 52 (54) | 72 (59) |
| Weight, median (range), kg | 50.9 (23.0–80.8) | 80.5 (47.3–128.0) | 73.9 (23.0–128.0) |
| BSA, median (range), m2 | 1.45 (0.9–1.9) | 1.9 (1.4–2.5) | 1.84 (0.9–2.5) |
| B‐cell count, median (range), 106 cells/L | 603 (197–2170) | 221 (10–2320) | 273 (10–2320) |
Abbreviations: BSA, body surface area; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis.
a
Three of 97 patients were aged 16 and 17 years.